First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

Abstract Background HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations. Methods This was a multicenter phase 1 study. HL-085 was administered twice daily in a standard 3 + 3 d...

Full description

Bibliographic Details
Main Authors: Xuan Wang, Zhiguo Luo, Jing Chen, Yu Chen, Dongmei Ji, Li Fan, Ling Chen, Qian Zhao, Pei Hu, Peng Sun, Zhongwei Jia, Jun Guo, Lu Si
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Medicine
Subjects:
HL-085
MEK inhibitor
Advanced melanoma
NRAS mutation, Circulating tumor DNA
Online Access:https://doi.org/10.1186/s12916-022-02669-7

Internet

https://doi.org/10.1186/s12916-022-02669-7

Similar Items